article thumbnail

What is TSW? New Study Seeks Clarity on Topical Steroid Withdrawal

The Dermatology Digest

“At the same time, there’s a patient group with different experiences, expressed as TSW, and their symptoms and the potential causes need to be investigated by means of both research and practical healthcare.

article thumbnail

Galderma’s Nemolizumab Approved for AD and PN in the UK and Switzerland

The Dermatology Digest

Just days after snagging dual approvals for moderate-to-severe atopic dermatitis (AD) and prurigo nodularis (PN) in the European Union, nemolizumab (Nemluvio, Galderma) was also granted Marketing Authorization in the United Kingdom (UK) and Switzerland for AD and PN.

article thumbnail

Patient Images Severely Lacking in AD Studies

The Dermatology Digest

Patient images are missing in studies of atopic dermatitis (AD), new research shows. “Images are also important for understanding that atopic dermatitis looks very different in different types of skin. This means that as little as 0.3 per thousand of the AD patients were represented in images in the published articles.

Eczema 74
article thumbnail

Oh, What a Year! The Skin of Color Society Reflects on Its Dynamic 2024

The Dermatology Digest

More than 200 residents, medical students and Fellow members have committed to volunteer for MBWS outreach events at universities, hospitals, and community venues, with a planned distribution of 10,000 gift bags with tips for managing winter skin and free moisturizing products generously provided by campaign sponsor, Clinique.

Webinar 78
article thumbnail

U.S. Dermatology Partners Welcomes Iris Gipson, MPAS, PA-C to Its Cushing, Oklahoma Office

US Dermatologt Partners

She has a passion for skin cancer surveillance and pediatric dermatology and is especially drawn to helping patients with atopic dermatitis, acne, and psoriasis. in the Hillcrest Hospital Cushing Campus. Dermatology Partners, she served as a Physician Assistant in dermatology at OU Health in Oklahoma City. Im thrilled to join U.S.

Office 41
article thumbnail

New Study Quantifies High Costs Incurred by Vitiligo Patients

The Dermatology Digest

” –Khaled Ezzedine, MD, PhD, of the Department of Dermatology at AP-HP at Henri Mondor University Hospital in Créteil, France, in a news release. medical equipment and home healthcare).

article thumbnail

Dr. Lawrence Eichenfield Unpacks New Phase 3 Data on Roflumilast Cream 0.05% in AD in Kids Aged 2 to 5

The Dermatology Digest

Late-breaking data showing that roflumilast cream 0.05% improved atopic dermatitis (AD) symptoms in kids between the ages of 2 to 5 as early as 24 hours following the first application, made a big splash at the recent American Academy of Dermatology meeting in San Diego, CA. Arcutis’ roflumilast cream 0.3% Additionally, 39.4%